220 related articles for article (PubMed ID: 34126361)
21. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
23. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
[TBL] [Abstract][Full Text] [Related]
24. The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Labroli MA; Dwyer MP; Shen R; Popovici-Muller J; Pu Q; Wyss D; McCoy M; Barrett D; Davis N; Seghezzi W; Shanahan F; Taricani L; Beaumont M; Malinao MC; Parry D; Guzi TJ
Bioorg Med Chem; 2014 Apr; 22(7):2303-10. PubMed ID: 24588962
[TBL] [Abstract][Full Text] [Related]
25. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
[TBL] [Abstract][Full Text] [Related]
27. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
Zeng C; Fan W; Zhang X
Cell Oncol (Dordr); 2015 Aug; 38(4):319-25. PubMed ID: 26092210
[TBL] [Abstract][Full Text] [Related]
28. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
[TBL] [Abstract][Full Text] [Related]
29. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Sigmond J; Bergman AM; Leon LG; Loves WJ; Hoebe EK; Peters GJ
Anticancer Drugs; 2010 Jul; 21(6):591-9. PubMed ID: 20436341
[TBL] [Abstract][Full Text] [Related]
30. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
[TBL] [Abstract][Full Text] [Related]
33. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
[TBL] [Abstract][Full Text] [Related]
34. A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells.
Taricani L; Shanahan F; Malinao MC; Beaumont M; Parry D
PLoS One; 2014; 9(11):e111714. PubMed ID: 25375241
[TBL] [Abstract][Full Text] [Related]
35. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
36. A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.
Specks J; Lecona E; Lopez-Contreras AJ; Fernandez-Capetillo O
Mol Cell Biol; 2015 Sep; 35(17):2910-7. PubMed ID: 26077802
[TBL] [Abstract][Full Text] [Related]
37. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
38. mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism.
Chawsheen MA; Dash PR
Cell Signal; 2021 May; 81():109934. PubMed ID: 33545231
[TBL] [Abstract][Full Text] [Related]
39. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
